Radar · Life Sciences in Cambridge
Best Life Sciences Companies in Cambridge, United States
The 631 best Life Sciences companies in Cambridge, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Moderna.
By Riya SenguptaFinancials
631companies tracked
$40.3Bdisclosed funding
1unicorns
435have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × CAMBRIDGE
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
1.2Mcombined LinkedIn audience
73%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Moderna Developer of mRNA-based therapeutics for a wide range of diseases 82Tech top 11%Funding top 15%Market top 22%Partners top 25% All 12 signals ▾Techtop 11% Fundingtop 15% Markettop 22% Partnerstop 25% Talenttop 25% Newstop 31% Moattop 32% Patentstop 34% Globaltop 38% Innovationtop 39% Growthbottom 49% Fin. healthbottom 48% Tech: 57 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Ses Funding: Raised $2.8B across 20 rounds · 20 rounds over 14 yrs (1.4/yr) rank vs industry peers · Fliar Intelligence Index 82/100 | $2.8B | 17 mo ago | 1,312 | 2010 | Apple iCloud MailMicrosoft 365TypeScript+24 | 31 patents Patents concentrated in health & consumer products | 1 internship |
| 2 | XtalPi 🦄 AI-based drug research and development company 64Funding top 18%AI top 26%Talent top 28%Patents top 31% All 13 signals ▾Fundingtop 18% AItop 26% Talenttop 28% Patentstop 31% Moattop 31% Innovationtop 34% Producttop 35% Newstop 38% Techtop 39% Growthtop 47% Globaltop 50% Marketbottom 43% Fin. healthbottom 32% Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $785M | 9 mo ago | 27 | 2014 | WordPressMySQLPHP+28 | 14 patents Small-molecule STING agonists and PI3Kβ inhibitors for immuno‑oncology therapeutics | 1 partnership |
| 3 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +12% | 2018 | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 4 | eGenesis Developer of a gene transplantation platform for humanizing pig cells 67Funding top 20%Product top 21%Patents top 23%Moat top 28% All 11 signals ▾Fundingtop 20% Producttop 21% Patentstop 23% Moattop 28% Innovationtop 32% Growthtop 38% Talenttop 38% Techtop 40% Marketbottom 44% Globalbottom 44% Newsbottom 18% Funding: Raised $481M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Product: 5 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 67/100 | $481M | 21 mo ago | 94 94 → 153 (+63%) · sector median +12% | 2015 | Craft CMSApple iCloud MailMicrosoft 365+17 | 61 patents Genetically engineered livestock for xenotransplant organ compatibility | 1 award |
| 5 | Vor Biopharma Developer of therapeutics to treat acute myeloid leukemia 78Funding top 12%Patents top 19%Innovation top 20%News top 24% All 10 signals ▾Fundingtop 12% Patentstop 19% Innovationtop 20% Newstop 24% Talenttop 27% Moattop 35% Growthtop 39% Techtop 40% Markettop 47% Globalbottom 40% Funding: Raised $477M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Patents: 188 patents matched (strict assignee match) · 154 filings since 2022 vs 34 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $477M | 6 mo ago | 133 | 2019 | WordPressApple iCloud MailMySQL+29 | 188 patents Patents concentrated in health & consumer products | — |
| 6 | In Silico AI-enabled bioinformatics platform for drug discovery and biomarker development 82Funding top 15%Product top 19%AI top 20%News top 26% All 12 signals ▾Fundingtop 15% Producttop 19% AItop 20% Newstop 26% Partnerstop 26% Talenttop 28% Moattop 31% Innovationtop 35% Growthtop 35% Markettop 43% Techtop 46% Globalbottom 39% Funding: Raised $400M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 82/100 | $400M | 17 mo ago | 300 | 2014 | SentryMUIReact+10 | — | — |
| 7 | Parabilis Medicines Developer of peptide therapeutics for the treatment of severe diseases 55Funding top 13%Growth top 35%Moat top 37%Patents top 39% All 9 signals ▾Fundingtop 13% Growthtop 35% Moattop 37% Patentstop 39% Innovationtop 43% Globaltop 50% Talentbottom 49% Techbottom 43% Marketbottom 40% Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $305M | 5 mo ago | — | 2016 | WordPressApple iCloud MailMySQL+19 | 11 patents Design and synthesis of stapled peptide therapeutics for targeted drug delivery | — |
| 8 | Arbor Biotechnologies Provider of genomic technologies and drug discovery platform 82Patents top 15%Innovation top 17%Funding top 19%Growth top 25% All 12 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 19% Growthtop 25% Producttop 25% Moattop 26% Talenttop 28% AItop 45% Markettop 47% Globalbottom 42% Techbottom 36% Newsbottom 27% Patents: 372 patents matched (strict assignee match) · 307 filings since 2022 vs 65 in 2017-21 Innovation: 372 patents (top 6% of patent-holders) · 307 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $300M | 7 mo ago | 117 117 → 102 (-13%) · sector median +12% | 2016 | — | 372 patents CRISPR nucleases and reverse transcriptase enzymes for genome editing platforms | 2 partnerships |
| 9 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 17 mo ago | 103 | 2020 | — | — | — |
| 10 | Cognito Therapeutics Developer of a medical device for the treatment of Alzheimer's disease 60Talent top 22%Funding top 23%Growth top 35%Moat top 42% All 8 signals ▾Talenttop 22% Fundingtop 23% Growthtop 35% Moattop 42% Techtop 50% Marketbottom 43% Globalbottom 37% Newsbottom 21% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $227M | 3 mo ago | 42 | 2016 | WebflowGSAPUnpkg+12 | — | — |
| 11 | Apnimed Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea 37Funding top 14%Growth top 28%Talent top 28%Moat top 35% All 12 signals ▾Fundingtop 14% Growthtop 28% Talenttop 28% Moattop 35% Producttop 40% Techbottom 49% Globalbottom 37% Patentsbottom 34% Marketbottom 32% Innovationbottom 21% Newsbottom 18% Customersbottom 3% Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $208M | 2 mo ago | 13 | 2017 | WordPressApple iCloud MailMySQL+21 | 2 patents Pharmaceutical solid‑form optimization and repurposed drug therapy for sleep‑apnea treatment | 1 job opening · 1 award |
| 12 | CAMP4 Provider of a drug prediction and development tool for researchers 53Funding top 17%Growth top 37%Moat top 39%Talent top 41% All 9 signals ▾Fundingtop 17% Growthtop 37% Moattop 39% Talenttop 41% AItop 45% Marketbottom 41% Globalbottom 37% Techbottom 26% Newsbottom 20% Funding: Raised $180M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Growth: Headcount 37 → 62 (+68%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $180M | 9 mo ago | 62 62 → 62 (+0%) · sector median +12% | 2018 | WordPressApple iCloud MailMicrosoft 365+13 | — | — |
| 13 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +12% | 2017 | DrupalPHPZURB Foundation+21 | — | — |
| 14 | Casma Therapeutics Developer of therapies for treating rare genetic disorders 40Funding top 20%Product top 30%Innovation top 38%Moat top 48% All 9 signals ▾Fundingtop 20% Producttop 30% Innovationtop 38% Moattop 48% Marketbottom 48% Growthbottom 41% Globalbottom 37% Newsbottom 22% Techbottom 21% Funding: Raised $154M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Product: 3 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 40/100 | $154M | 3 mo ago | 38 | 2017 | — | — | — |
| 15 | Judo Bio Developer of therapeutics for systemic and renal diseases | $150M | 20 mo ago | — | 2021 | WordPressMySQLPHP+15 | — | 1 job opening |
| 16 | QurAlis Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) 64Funding top 20%Patents top 23%Innovation top 25%Growth top 26% All 10 signals ▾Fundingtop 20% Patentstop 23% Innovationtop 25% Growthtop 26% Moattop 32% Talenttop 41% Techbottom 43% Globalbottom 42% Marketbottom 36% Newsbottom 22% Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 9 mo ago | 38 38 → 87 (+129%) · sector median +12% | 2016 | WordPressApple iCloud MailMicrosoft 365+17 | 69 patents Antisense oligonucleotide therapeutics targeting UNC13A for neurological disease treatment | — |
| 17 | Harbinger Health AI-based cancer detection tool for providers 55Funding top 18%News top 36%Moat top 42%AI top 45% All 8 signals ▾Fundingtop 18% Newstop 36% Moattop 42% AItop 45% Talenttop 49% Techbottom 48% Marketbottom 43% Globalbottom 38% Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership rank vs industry peers · Fliar Intelligence Index 55/100 | $140M | 2 mo ago | 60 | 2008 | WordPressApple iCloud MailMySQL+23 | — | 2 launchs |
| 18 | Diagonal Therapeutics Developer of antibody therapeutics for the treatment of rare diseases 40Funding top 19%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 19% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 38% Funding: Raised $128M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $128M | 5 mo ago | — | 2022 | — | — | — |
| 19 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | 2019 | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 20 | Akamis Bio Developer of therapeutics for the treatment of colorectal cancer | $119M | 18 mo ago | 81 | 2010 | WordPressMySQLPHP+14 | — | — |
| 21 | Stipple Bio Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target… 21Funding top 20%Talent top 38%Global bottom 48%Tech bottom 25% All 5 signals ▾Fundingtop 20% Talenttop 38% Globalbottom 48% Techbottom 25% Marketbottom 19% Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $109M | 2 mo ago | 2 | 2021 | WordPressMySQLPHP+11 | — | 1 partnership |
| 22 | Mediar Therapeutics Developer of antibody-based therapeutics for treating fibrosis 19Funding top 25%Moat top 48%Talent bottom 49%News bottom 42% All 6 signals ▾Fundingtop 25% Moattop 48% Talentbottom 49% Newsbottom 42% Globalbottom 39% Marketbottom 21% Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $105M | 6 mo ago | 2 | 2018 | — | — | — |
| 23 | Strand Therapeutics Provider of platform to deliver mRNA therapeutics for multi functional treatments 64Growth top 13%Funding top 24%Moat top 31%News top 41% All 7 signals ▾Growthtop 13% Fundingtop 24% Moattop 31% Newstop 41% Talenttop 41% Globalbottom 39% Marketbottom 38% Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $103M | 12 mo ago | 47 | 2017 | — | — | 2 awards |
| 24 | Vaxess Developer of novel vaccine formulations using silk stabilization platform | $100M | 9 mo ago | 49 | 2011 | — | 8 patents Patents concentrated in health & consumer products | 1 job opening |
| 25 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | 33 | 2021 | — | — | — |
| 26 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | 2014 | WordPressApple iCloud MailMySQL+22 | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 27 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | 2018 | — | — | — |
| 28 | AIRNA Developer of gene therapies for rare and common diseases | $90M | 14 mo ago | — | 2021 | WordPress Block EditorWordPressApple iCloud Mail+26 | 6 patents RNA editing using chemically modified antisense oligonucleotides and targeted delivery | 1 partnership |
| 29 | Actithera Radiopharmaceutical company developing novel radiotherapeutics for the treatment of cancer through its unique… | $81M | 11 mo ago | — | 2021 | WordPressMySQLPHP+19 | — | — |
| 30 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | 2021 | — | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 31 | Zag Bio Developer of thymus-targeted medicines for autoimmune disease treatment and prevention | $80M | 7 mo ago | — | 2022 | — | — | — |
| 32 | Immuneering Corporation Provider of an AI-enabled bioinformatics platform for clinical solutions | $79M | 9 mo ago | 73 73 → 60 (-18%) · sector median +12% | 2019 | DrupalPHPZURB Foundation+25 | 45 patents MEK1/2 kinase inhibitors for oncology immunotherapy, especially pancreatic cancer treatment | — |
| 33 | Metaphore Provider of machine language and computational platform for drug discovery 42Funding top 23%Talent top 28%Moat top 42%AI top 45% All 7 signals ▾Fundingtop 23% Talenttop 28% Moattop 42% AItop 45% Globalbottom 36% Techbottom 35% Marketbottom 31% Funding: Raised $50.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $50M | 2 mo ago | 30 | 2021 | WebflowMicrosoft 365jQuery+4 | — | — |
| 34 | Kytopen Developer of gene delivery systems for cell therapy 50Funding top 21%Talent top 28%Moat top 32%Patents top 33% All 8 signals ▾Fundingtop 21% Talenttop 28% Moattop 32% Patentstop 33% Innovationtop 36% Globalbottom 40% Marketbottom 28% Newsbottom 22% Funding: Raised $43.1M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $43M | 2 mo ago | 12 12 → 27 (+125%) · sector median +12% | 2017 | — | 31 patents Automated electro‑mechanical transfection systems for gene and cell delivery | — |
| 35 | WaveGuide Portable micro-nuclear magnetic resonance instruments for on-site testing and analysis | $41M | 13 mo ago | 6 | 2010 | — | 26 patents Low-field NMR instrumentation with advanced programmable-gain and switched-mode amplifiers | — |
| 36 | Pinetree Therapeutics Developer of disruptive therapies for oncology and infectious diseases | $40M | 7 mo ago | 9 | 2019 | — | — | — |
| 37 | Kernal Biologics Developer of mRNA therapeutics for immuno-oncology using deep learning technology | $35M | 8 mo ago | 18 18 → 22 (+22%) · sector median +12% | 2016 | — | 27 patents Targeted lipid-based delivery systems for oncoselective cancer therapeutics | — |
| 38 | PAQ Developer of small molecule therapeutics for neurodegenerative disease 24Funding top 27%Talent top 28%Moat top 39%News top 46% All 8 signals ▾Fundingtop 27% Talenttop 28% Moattop 39% Newstop 46% Patentsbottom 41% Globalbottom 37% Innovationbottom 33% Marketbottom 24% Funding: Raised $34.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $34M | 4 mo ago | 6 | 2020 | — | 10 patents Airtight, child‑resistant, compartmentalized packaging for tobacco products | — |
| 39 | Hopewell Therapeutics Provider of a synthetic lipid-based drug delivery solution | $32M | 9 mo ago | 26 | 2018 | — | — | — |
| 40 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | 48 | 2013 | — | — | — |
| 41 | Solarea Bio Innovating microbial solutions for human health, focusing on aging well 29Funding top 29%Moat top 39%Tech top 43%News top 44% All 7 signals ▾Fundingtop 29% Moattop 39% Techtop 43% Newstop 44% Talentbottom 49% Globalbottom 36% Marketbottom 29% Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | 7 mo ago | 24 | 2017 | SanityNode.jsHeadless UI+9 | — | — |
| 42 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +12% | 2015 | WordPress Block EditorWordPressMySQL+15 | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 43 | Leap Therapeutics Developing targeted and immuno-oncology therapeutics for cancer patients 35Product top 14%Funding top 30%Innovation top 34%Tech top 49% All 10 signals ▾Producttop 14% Fundingtop 30% Innovationtop 34% Techtop 49% Moatbottom 45% Newsbottom 42% Growthbottom 39% Globalbottom 37% Marketbottom 35% Fin. healthbottom 30% Product: 4 distinct product lines · Company stage: Public Funding: Raised $24.7M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $25M | 8 mo ago | 44 | 2011 | DrupalPHPAmazon Web Services+20 | — | — |
| 44 | Ketryx Provider of AI-native compliance software for regulated medical applications development 45Funding top 30%Tech top 40%AI top 45%Growth top 48% All 9 signals ▾Fundingtop 30% Techtop 40% AItop 45% Growthtop 48% Talentbottom 49% Moatbottom 48% Marketbottom 32% Newsbottom 31% Globalbottom 29% Funding: Raised $18.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Tech: 36 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 45/100 | $18M | 11 mo ago | 19 | 2021 | WebflowSentryWistia+32 | — | — |
| 45 | Violet Therapeutics Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS 48Talent top 38%Funding top 39%Global bottom 48% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 48% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $15.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $15M | 1 mo ago | — | 2021 | — | — | — |
| 46 | AltrixBio Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases | $13M | 9 mo ago | 5 | 2019 | — | 2 patents Mucoadhesive drug delivery formulations for targeted mucosal administration | — |
| 47 | EnClear Therapies Precision dosing for CNS diseases through innovative neurotechnology platform | $13M | 11 mo ago | 12 | 2018 | — | 79 patents CSF-based drug delivery, monitoring, and pressure control for neuro‑oncology therapies | — |
| 48 | NeuroBionics Developer of bioelectronic fibers for neuromodulation and neural interface applications | $10M | 6 mo ago | — | 2023 | WordPressMySQLPHP+21 | 2 patents Implantable neural fiber interfaces for bioelectronic signal recording and stimulation | 3 job openings |
| 49 | OS Therapies Developer of therapies for treating cancer | $8M | 3 mo ago | 5 | 2017 | WordPressMySQLPHP+28 | 10 patents Ocular drug delivery formulations and handheld thermal devices for eye surface disorders | — |
| 50 | QSimulate Laboratory focused on developing of quantitative simulation tools to help in quantum molecular 32Growth top 35%Talent top 38%Funding top 41%Moat top 48% All 7 signals ▾Growthtop 35% Talenttop 38% Fundingtop 41% Moattop 48% Techbottom 36% Globalbottom 36% Marketbottom 24% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 32/100 | $4M | 6 mo ago | 14 14 → 21 (+50%) · sector median +12% | 2018 | UbuntuYouTubeBootstrap+6 | — | 1 job opening |
Top 12 Life Sciences companies in Cambridge
#1
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees$207.8Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees
Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Talent
top 28%Moat
top 35%Product
top 40%Tech
bottom 49%Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Conventional Debt (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 22k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Director, Field Medical Affairs
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Mar 2026Series C$25M
- Sep 2025Conventional Debt$35M
- Apr 2025Series C$16.5M
Founders & team
Investors
Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign
#2
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees$227Mraised▾
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees
Developer of a medical device for the treatment of Alzheimer's disease. The device uses gamma stimulation which helps in reactivating the immune system of the brain. It results in the reduction of amyloid plaques and tau tangles which are typical hallmarks of the disease.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Talent
top 22%Funding
top 23%Growth
top 35%Moat
top 42%Tech
top 50%Market
bottom 43%Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series C (Mar 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 15k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Ochsner Health) announced in 12 mo
Funding rounds
- Mar 2026Series C$105M
- Mar 2025Series C$196.3M
- Jun 2024Series B$10.2M
- Jun 2022Series B$108.8M
Founders & team
Investors
Morningside, FoundersX Ventures, Alzheimer's Drug Discovery, LIfT Biosciences, IAG Capital Partners, WS Investment Company
Tech stack
CdnjsCloudflareCraft CmsFacebook PixelGoogle AnalyticsGoogle Tag Manager
#3
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#4
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees$140Mraised▾
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees
AI-based cancer detection tool for providers. The company has developed a blood test detection tool that enables professionals to analyze and detect early cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 18%News
top 36%Moat
top 42%AI
top 45%Talent
top 49%Tech
bottom 48%Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Apr 2026)
News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$100M
- Sep 2023Series B$140M
- 2021Series A$50M
Founders & team
Investors
Flagship Pioneering, Pictet Group, Partners Investment, Venture Catalysts, M&G, Camillus LifeSciences
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font Api
#5
Public · Cambridge, Massachusetts · founded 2019 · 133 employees$477.1Mraised▾
Public · Cambridge, Massachusetts · founded 2019 · 133 employees
Developer of therapeutics to treat acute myeloid leukemia. The company has developed cancer therapeutics using engineered hematopoietic stem cells (eHSC). The company's lead candidate includes VOR33 which targets CD33 protein in cancer patients to treat acute myeloid leukemia (AML).
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 12%Patents
top 19%Innovation
top 20%News
top 24%Talent
top 27%Moat
top 35%Funding: Raised $477M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Post IPO (Dec 2025)
Patents: 188 patents matched (strict assignee match) · 154 filings since 2022 vs 34 in 2017-21 · Latest publication 2026
Innovation: 188 patents (top 13% of patent-holders) · 154 filings since 2022 vs 34 in 2017-21
Funding rounds
- Dec 2025Post IPO$150M
- Jun 2025Post IPO$175M
- Jul 2020Series B$110.1M
- Feb 2019Series A$42M
Founders & team
Investors
RA Capital Management, Forbion, Venrock, Caligan Partners, NEXTBio, Mingxin Capital
Tech stack
AddtoanyAddtoany Share ButtonsApple Icloud MailCloudflareCloudflare Bot ManagementCookiebot
#6
Series C · Cambridge, Massachusetts · founded 2017 · 38 employees$154.5Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 38 employees
Casma Therapeutics is developing therapies for treating rare genetic disorders. They are focused on autophagy of rare genetic diseases which helps in restoring cellular balance and reversing the course of the disease. The technology enables initiation, the formation of the autophagosome, fusion with lysosomes, and lysosomal biogenesis.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 20%Product
top 30%Innovation
top 38%Moat
top 48%Market
bottom 48%Growth
bottom 41%Funding: Raised $154M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Grant (prize money) (Mar 2026)
Product: 3 distinct product lines · Company stage: Series C
Innovation: 3 product lines
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Grant (prize money)$7.6M
- Nov 2022Series C$46M
- Sep 2020Series B$50M
- May 2018Series A$58.5M
Investors
The Column Group, Eventide Funds, Schroders Capital, Third Rock Ventures, Amgen, Astellas Venture Management
Tech stack
WordpressMysqlPhpNginxWp Engine
#7
XtalPi 🦄Public · Cambridge, Massachusetts · founded 2014 · 27 employees$784.8Mraised▾
XtalPi 🦄
Public · Cambridge, Massachusetts · founded 2014 · 27 employees
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The company's algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 18%AI
top 26%Talent
top 28%Patents
top 31%Moat
top 31%Innovation
top 34%Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
AI: Classified as an AI company · Product described with: ai-based, machine learning
Talent: Analyst team rating 4/5
Audience (LinkedIn): 18k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. OpenEye, Cadence Molecular Sciences) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$268M
- Feb 2025Post IPO$268.4M
- Aug 2021Series D$400M
- Sep 2020Series C$318.8M
Investors
Tencent, Frees Fund, Zhen Fund, Renren, SoftBank Vision Fund, People's Insurance Company of China
Tech stack
Animate.CssBootstrapCdnjsCloudflareCloudflare Bot ManagementCore-Js
#8
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees$109.5Mraised▾
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees
Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery. The platform technology enables single-cell profiling and target identification for ddrug discovery and development of cancer immunotherapy and others.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Global
bottom 48%Tech
bottom 25%Market
bottom 19%Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 1 country beyond United States
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Lonza) announced in 12 mo
Funding rounds
- Mar 2026Series A$100M
- Dec 2024Series A$9.5M
Founders & team
Investors
RA Capital Management, Andreessen Horowitz, Nextech Invest, Emerson Collective, Google Ventures, GordonMD Global Investments
Tech stack
AstraCore-JsElementorGoogle Font ApiGoogle Hosted LibrariesJquery
#9
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#10
Series F · Cambridge, Massachusetts · founded 2016$305Mraised▾
Series F · Cambridge, Massachusetts · founded 2016
Developer of peptide therapeutics for the treatment of severe diseases. It offers a proprietary AI- and physics-based computational methods as discovery platform . It offers FOG-001 an inhibitor of β-catenin:TCF for colorectal cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 13%Growth
top 35%Moat
top 37%Patents
top 39%Innovation
top 43%Global
top 50%Funding: Raised $305M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series F (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: IP moat: 11 patents · Soonicorn · 9 curated direct competitors tracked
Funding rounds
- Jan 2026Series F$305M
Founders & team
Investors
RA Capital Management, Fidelity Investments, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, Arch Venture Partners
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementDocusignDraftpress HfcmFont Awesome
#11
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees$100Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees
Developer of allosteric therapeutics for precision oncology and rare diseases. The company integrated with proprietary drug discovery platform that enables to unlock novel allosteric binding pockets and rapidly advance structural insights into small molecule therapeutics designt to unlock cryptic allosteric sites across a broad range of target classes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 19%Talent
top 28%Moat
top 31%Market
bottom 42%Global
bottom 36%News
bottom 33%Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Mar 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Mar 2026Series B$40M
- Dec 2025Series B$120M
- Dec 2023Series A$40M
- Aug 2021Series A$60M
Founders & team
Investors
The Column Group, Lux Capital, Nextech Invest, Regeneron Ventures, RA Capital Management
#12
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees$80Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Moat
top 36%News
top 38%Talent
top 38%Innovation
top 48%Patents
bottom 49%Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
News: 3 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Series B$77M
- Sep 2025Series A$30.2M
- Jul 2023Series A$80M
Founders & team
Investors
Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly
Funding & investor landscape
$40.3Btotal disclosed funding
441companies funded
1,612disclosed rounds
9rounds last 90 days
Most active investors
Atlas Venture43 rounds
Notable founders
Andrew Wellman
Co-Founder · Apnimed
Lawrence Miller
Co-Founder · Apnimed
Ed Boyden
Co-Founder · Cognito Therapeutics
Li-Huei Tsai
Co-Founder · Cognito Therapeutics
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Stephen Hahn
CEO · Harbinger Health
Siddhartha Mukherjee
Founder · Vor Biopharma
Robert Ang
President and CEO · Vor Biopharma
Aaron Ring
Co-Founder · Stipple Bio
Aashish Manglik
Co-Founder · Stipple Bio
Mathai Mammen
CEO · Parabilis Medicines
Ralph DeBerardinis
Co-Founder · Atavistik
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CAMBRIDGE · Health & Bio
How research on Biotechnology in Cambridge is moving
A read on the academic research around Biotechnology in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 62 papers.
University of Cambridge leads optimistic biotech research (mean stance 0.58) dominated by plant molecular biology and epigenetics, with breakthroughs surging recently (44 post-2020 vs 18 pre-2020).
62 papers · stance +0.58 · 46% breakthrough · 14% concern
top institutions
- University of Cambridge54
- Cambridge School4
- Cambridge University Hospitals NHS Foundation Trust4
- Cancer Research UK Cambridge Center3
- Cambridge Life Sciences1
leading researchers
Facundo Romani · Ho‐Ming Chen · Jeanne Salje · Kanu Patel · V.G. MELNIKOV · A.K. SADANOV
prism intelligence · tone & topics
92% positive · 5% critical tone
Medical ResearchHealthPharmaceuticalsAgricultureBiologyGenetics
▲
Breakthroughs27 · 44%
▲ 33%→47% share
▲1.4× share momentum0 median citations74% since 2021mostly empirical
DNA methylation and Mitochondrion research newly emerging, driving Breakthroughs field-share from 33% to 47%.
rising sub-themes (early→recent)
- Chromatin1→3
Newly emergingMitochondrion 0→3 · DNA methylation 0→3
Landmark A MicroRNA Superfamily Regulates Nucleotide Binding Site–Leucine-Rich Repeats and Other mRNAs · 745 cites
◆
Advancements24 · 39%
▼ 42%→37% share
▼0.9× share momentum0 median citations71% since 2021mostly empirical
Advancements field-share cooling 42%->37% despite Antibody papers rising to 3.
rising sub-themes (early→recent)
- Antibody3
- Fermentation2
- Gene2
- Transcription (linguistics)2
- Probiotic2
Landmark Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity · 1,150 cites
▼
Concerns8 · 13%
▼ 17%→12% share
▼0.7× share momentum1 median citations62% since 2021mostly empirical
Concerns field-share shrinking 17%->12%, though Cell adhesion research ticking upward to 1.
rising sub-themes (early→recent)
- Cell adhesion1
- Cell adhesion molecule1
- Follicular dendritic cells1
- Endocytosis1
- Neural cell adhesion molecule1
Landmark Life-Cycle Assessment of Potential Algal Biodiesel Production in the United Kingdom: A Comparison of Raceways and Air-Li · 556 cites
Common questions
How many Life Sciences companies are there in Cambridge, United States?
Radar tracks 631 indexable Life Sciences companies headquartered in Cambridge, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Cambridge, United States?
The Life Sciences companies in Cambridge, United States on this list have raised a combined $40.3B in disclosed equity funding across 441 funded companies.
Which is the highest-funded Life Sciences company in Cambridge, United States?
Moderna is the highest-funded Life Sciences company in Cambridge, United States, with $2.8B in disclosed equity funding.
How many Life Sciences companies in Cambridge, United States are funded?
441 of the 631 Life Sciences companies in Cambridge, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Cambridge, United States?
1 Life Sciences company in Cambridge, United States on this list is valued at $1B or more.
Who are the top investors in Cambridge, United States Life Sciences companies?
The most active investors in Cambridge, United States Life Sciences companies on this list include HHS, Atlas Venture, Flagship Pioneering, Alexandria, Arch Venture Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.